A Deep Dive in SRPT Chart!

Sarepta Therapeutics, Inc. (SRPT) -Nasdaq During the past six weeks we had so many stories, with or against SRPT approval, where a 10-million shares short sellers are still traped in.

Biotech Inflection Point – Watch List-2

  Following my last technical analysis “Biotech Inflection Point – Watch List-1” I will keep adding names to our watch list with some beaten down tickers, we can find many.

Biotech Inflection Point – Watch List-1

  Following my last technical analysis “XBI – A Look At The Near and Long Term In The Biotech Sector” I will start adding names to our watch list with.

XBI – A Look At The Near and Long Term In The Biotech Sector

  SPDR S&P Biotech ETF (XBI)–NYSE   We will maintain our focus on the XBI as the biotech barometer, many are waiting for the XBI to outperform the IBB again.

The XBI In The Take Or Break Zone!

  SPDR S&P Biotech ETF (XBI)–NYSE   We will maintain our focus on the XBI as the biotech barometer. After the double bottom around 59 points a month ago, the.

2 Biotech Stocks In The Breakout Territory

  Biotech traders have to adapt to any changes in the stock market, trying to adjust their trades and the game plan along with the markets condition. It is easier.

SRPT Breakout- A Quick Look At The Chart

  Sarepta Therapeutics, Inc. (SRPT) – Nasdaq   After three years of a roller coaster, Sarepta getting closer to the the real deal, started with the NDA acceptance by the FDA on.

A Quick look – XBI In The Decision Zone

SPDR S&P Biotech ETF (XBI) We will maintain our focus on the XBI as the biotech barometer. Noticing lately the fact XBI is outperforming the IBB & the broader market.

BioBlast Pharma: an under the radar ultra-rare disease company

  Bio Blast Pharma Ltd. (ORPN) – Nasdaq BioBlast Pharma (ORPN) is a clinical-stage biotech company, focused on treatments for rare and ultra-rare diseases, especially genetic and metabolic diseases. The company has three.

TRIL – Preparing For The Next Move Upward

  Trillium Therapeutics Inc. (TRIL) – Nasdaq Trillium (TRIL) is developing the next-generation of cancer immunotherapies. TRIL’s lead program, SIRPαFc, targets CD47 to prevent cancer cells from delivering a “do not eat”.

BMY – Is the Technical Correction Done ?

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $47.54 in mid October 2014 to reach a new 12 years high.

Adamas Pharmaceuticals – Volatility Squeeze Action

  Adamas Pharmaceuticals, Inc. (ADMS) –Nasdaq   Adamas pharmaceutical had its initial public offering last year April 10th, the closing of its IPO of 3 million shares at a public offering.

Quick update: The IBB – Negative Divergence

iShares Nasdaq Biotechnology (IBB) – Nasdaq As tweeted several time last and early this week, signs of weakness in the IBB Signs of weakness in the $IBB ..Start forming a Bearish.

IBB – XLV Biotech Sector Post JP-Morgan Conference

  iShares Nasdaq Biotechnology (IBB) – Nasdaq Health Care Select Sector SPDR ETF (XLV)–NYSE   The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV..

BMY – A Bull Flag Breakout or A Head Fake

  Bristol-Myers Squibb Company (BMY)  -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach.

Caution, SPY – Forming A Rare Tri-Star Pattern

  SPDR S&P 500 ETF (SPY) –NYSE The SPY had an extreme price action during the last two months after reaching the All-Time-High 201.90 points on September 19th, followed by a.

MRK – A Falling Knife Or a Golden Opportunity

  Merck & Co. Inc. (MRK) -NYSE Many speculation going around the huge drop in MRK’s share price in just one week, dropping from the $60.18 (closing on 10/08) to reach.

CNAT – A Quick Chart Update

  Conatus Pharmaceuticals Inc. (CNAT) –Nasdaq CNAT was trading within a downtrend channel since June 16th after reaching the high of $9.90, finding a base around the $6.00 weekly support line.

SRPT- A Squeeze In The Making

  Sarepta Therapeutics, Inc. (SRPT)-Nasdaq   Sarepta is preparing for a busy 4th quarter ahead of the NDA submission as confirmed again by the company’s CEO Chris Garabedian during the Morgan.

Merck – Preparing For The Next Move

  Merck & Co. Inc. (MRK) -NYSE   Lately, Merck was under the spot light after Idenix Pharmaceuticals deal, paying $3.85 Billion more than triple Idenix’s market capitalization before the deal.

SPY – A Quick Look at The Broader Market

SPDR S&P 500 (SPY) –NYSE   Yesterday we got a sharp turn in the SP-500 as the daily chart of the SPY (S&P 500 ETF) drops sharply and breaks down the.

Tekmira – Is It The Bottom Yet

  Tekmira Pharmaceuticals Corp (TKMR) –Nasdaq   Tekmira is the new “fallen star” after the wild run started Jan 07th, 2014 from $7.66, and reaching the all time high $31.48 mid.

BMY – In The Inflection Point

  Bristol-Myers Squibb Company (BMY) –NYSE   Bristol-Myers Squibb Co. (BMY) had a wild year, up from the lows of $41.11 in late August 2013 to reach a new 12 years.

RTRX – In a Consolidation Mode

Retrophin, Inc. (RTRX) –Nasdaq   During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation.

IBB – In the Decision Zone

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.

Progenics: Consolidation Ahead of the AdCom

Progenics Pharmaceuticals, Inc. (PGNX) -Nasdaq   Relistor has been approved by regulatory authorities in the U.S., countries in the E.U., Canada and Australia since 2008 for treatment of OIC in advanced-illness.

IBB – Biotech Sector in The Despondency Point

iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.

Pfizer – Technical points to watch

Pfizer Inc. (PFE) -NYSE A long awaited date from Pfizer revealed on Sunday April 04, 2014 at the AACR-2014. Pfizer  announced detailed results from the PALOMA-1 study, a randomized Phase 2 study.

IBB – In The Decision Zone

iShares Nasdaq Biotechnology (IBB) -Nasdaq The best indicator for our biotech portfolios are biotechnology indices such as IBB, NBI, XBI or XLV. By looking at the IBB daily chart, we get the.

BMY – Quick Chart Update

Bristol-Myers Squibb Company (BMY)  -NYSE   Interesting price action since September 9th after breaking out the downtrend line around $41.90, we kept watching the chart day after day during the preparation.

ONTX – Looking For The Reversal Pattern

Onconova Therapeutics, Inc. (ONTX) -Nasdaq   Onconova has recently plunged about $19 from the 52-week high at $31.13, reached just a month ago to the current level in mid-$13s and reaching the.

Browsing 31 / 52 articles
    1 2